: Novo Nordisk says semaglutide 2.4 mg reduces risk of major adverse cardiovascular events by 20% in adults with obesity

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Generated by Feedzy